GPCR Stock Risk & Deep Value Analysis
Structure Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About GPCR Stock
We analyzed Structure Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran GPCR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
GPCR Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is a negative or disappointing outcome from the Phase 2b clinical trial for GSBR-1290. Given the company's primary valuation driver is this lead asset, a clinical failure would severely impair the stock price and potentially lead to a rapid and substantial decline (e.g., 60-80% or more).
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Lack of recent financial reporting (no Q1 2026/Q4 2025 earnings identified, no profitability, balance sheet, or cash flow data available from recent searches).
- ⚠
Undetermined cash burn rate and cash runway due to lack of financial statements, creating funding uncertainty for a clinical-stage biotech.
- ⚠
Absence of institutional ownership percentage or analyst coverage makes it difficult to gauge market conviction outside of retail.
Upcoming Risk Events
- 📅
Negative or inconclusive Phase 2b data for GSBR-1290
- 📅
Significant clinical delays or regulatory hurdles
- 📅
Increased competitive pressure from other oral GLP-1 programs
When to Reconsider
- 🚪
Negative Phase 2b clinical trial results for GSBR-1290 (efficacy or safety failures).
- 🚪
Significant and unexpected delays in clinical trial timelines or regulatory filings.
- 🚪
Announcements of superior oral GLP-1 candidates from competitors with advanced data.
Unlock GPCR Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Structure Therapeutics Inc (GPCR) Do?
Market Cap
$3.75B
Sector
Healthcare
Industry
Biotechnology
Employees
218
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Visit Structure Therapeutics Inc WebsiteInvestment Thesis
Structure Therapeutics presents a high-risk, high-reward investment opportunity predicated on the successful clinical development and commercialization of its oral GLP-1 receptor agonist, GSBR-1290, for the massive obesity and diabetes markets. Leveraging its unique GPCR platform, positive Phase 2b data mid-2026 could unlock substantial value and position the company as a future leader in oral metabolic disease therapies.
Is GPCR Stock Undervalued?
Unlock the full AI analysis for GPCR
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
GPCR Price Targets & Strategy
12-Month Target
$175.00
Bull Case
$250.00
Bear Case
$20.00
Valuation Basis
Based on potential re-rating to peer multiples for successful oral GLP-1 candidates post-positive Phase 2b data, implying a significant increase in market cap reflecting blockbuster potential.
Entry Strategy
Given the binary nature of the upcoming Phase 2b data, dollar-cost averaging into a position leading up to mid-2026 or initiating a speculative position post-positive data confirmation, assuming a significant gap-up.
Exit Strategy
Take initial profits if stock approaches $150-$180 post-positive data. Consider full exit on negative Phase 2b results or if significant new competitive threats emerge. Stop loss below pre-catalyst support levels, e.g., $40.
Portfolio Allocation
5% for aggressive risk tolerance, reflecting high-risk, high-reward biotech speculation.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is GPCR Financially Healthy?
Valuation
P/E Ratio
-66.96
Forward P/E
-26.71
PEG Ratio
-2.37
Price/Book
2.50
Profitability
Return on Equity
-22.28%
EPS
$-0.49
Balance Sheet
Current Ratio
24.81
Quick Ratio
24.43
Debt/Equity
0.05
Cash & Equivalents
$927.00M
Other
Beta (Volatility)
-1.16
Does GPCR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat, primarily based on intellectual property surrounding its GPCR platform and specific drug candidates like GSBR-1290, is expanding contingent on successful clinical trials and subsequent patent protection. Durability will depend on robust clinical outcomes and the ability to fend off competitive offerings.
Moat Erosion Risks
- •Clinical trial failures that invalidate the efficacy or safety of their drug candidates.
- •Intense competition in the GLP-1 space, including other oral formulations from larger pharmaceutical companies.
- •Patent expirations or challenges that erode exclusivity.
GPCR Competitive Moat Analysis
Sign up to see competitive advantages
GPCR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - Data unavailable to confirm strong social media trends, likely driven by speculation around GLP-1 catalyst.
Institutional Sentiment
Neutral - No analyst consensus, price targets, upgrades, or downgrades found in recent market intelligence.
Insider Activity (Form 4)
CFO Yoon Jun received a grant of 128,892 employee stock options (exercise price $16.82/share) expiring March 18, 2036, vesting 1/4 on March 1, 2027, and monthly thereafter. Also received 104,085 RSUs vesting in 4 equal annual installments starting March 1, 2026. This activity represents equity grants, not open market buys or sells by the CFO.
Options Flow
Normal options activity - No specific unusual options flow identified from recent market intelligence.
Earnings Intelligence
Next Earnings
No expected date or consensus EPS/revenue estimates found as of 2026-04-12.
Surprise Probability
Low - Cannot be determined due to lack of previous earnings reports and estimates.
Historical Earnings Pattern
Undeterminable - No historical earnings reports or subsequent stock reactions identified in the provided data.
Key Metrics to Watch
Competitive Position
Top Competitor
LLY
Market Share Trend
Undeterminable - Structure Therapeutics is pre-commercialization and does not have current market share in the GLP-1 space.
Valuation vs Peers
Cannot provide a direct quantitative comparison for GPCR due to lack of traditional valuation metrics. However, successful GLP-1 developers and commercialization companies like Eli Lilly trade at significant premiums reflecting the market opportunity.
Competitive Advantages
- •Proprietary GPCR-focused discovery platform enabling novel oral small molecule therapies.
- •Potential first-in-class oral GLP-1 receptor agonist (GSBR-1290) offering convenience over injectables.
- •Experienced leadership team with expertise in drug development.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive GPCR Stock Higher?
Near-Term (0-6 months)
- •Phase 2b data readout for GSBR-1290 (oral GLP-1) targeting obesity/diabetes (mid-2026)
Medium-Term (6-18 months)
- •Potential strategic partnership announcements post-positive GSBR-1290 data
- •Advancement of other pipeline assets through preclinical/early clinical stages
Long-Term (18+ months)
- •Establishment of market leadership in oral GLP-1 segment
- •Broad utilization and commercialization of the GPCR-focused platform
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for GPCR?
- ✓
Positive and statistically significant Phase 2b data for GSBR-1290, particularly on weight loss and glucose control metrics.
- ✓
Formation of strategic partnerships or licensing agreements for GSBR-1290 or other pipeline assets.
- ✓
Any indications of positive financial updates or improved transparency regarding cash position.
Bull Case Analysis
See what could go right with Premium
Competing with GPCR
See how Structure Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Structure Therapeutics Inc GPCR | $3.8B | 7.7 | -67.0 | — | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Structure Therapeutics Inc Makes Money
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule medicines that modulate G protein-coupled receptors (GPCRs). Its primary focus is on advancing GSBR-1290, an oral GLP-1 receptor agonist, through clinical trials for the treatment of metabolic diseases such as obesity and type 2 diabetes. The company's business model relies on the successful development, regulatory approval, and eventual commercialization or out-licensing of its drug candidates, aiming to generate revenue from product sales or milestone payments and royalties from partnerships.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Structure Therapeutics Inc (GPCR)?
As of April 12, 2026, Structure Therapeutics Inc has a DVR Score of 7.7 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Structure Therapeutics Inc?
Structure Therapeutics Inc's market capitalization is approximately $3.8B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Structure Therapeutics Inc use?
GPCR is the ticker symbol for Structure Therapeutics Inc. The company trades on the NGM.
What is the risk level for GPCR stock?
Our analysis rates Structure Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of GPCR?
Structure Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -67.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Structure Therapeutics Inc's revenue growing?
Structure Therapeutics Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is GPCR stock profitable?
Structure Therapeutics Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the GPCR DVR analysis updated?
Our AI-powered analysis of Structure Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 12, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for GPCR (Structure Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.